AI assistant
KIORA PHARMACEUTICALS INC — Director's Dealing 2021
Nov 22, 2021
35256_dirs_2021-11-22_4be205c4-1f1d-4b07-80a8-e7e621a3b118.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: KIORA PHARMACEUTICALS INC (KPRX)
CIK: 0001372514
Period of Report: 2021-10-21
Reporting Person: Strem Brian M. (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-10-21 | Common Stock | A | 9517 | — | Acquired | 9517 | Direct |
| 2021-11-18 | Common Stock | P | 17853 | $1.41 | Acquired | 27370 | Direct |
Footnotes
F1: Received by the Reporting Person in connection with the acquisition by the issuer of all of the outstanding securities of Bayon Therapeutics, Inc. on October 21, 2021.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.395 to $1.41, inclusive. The reporting person hereby undertakes to provide to Kiora Pharmaceuticals, Inc., any security holder of Kiora Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.